Pasithea Therapeutics Corp. KTTA 深 滬
等待開盤 07-22 09:30:00 美东时间
0.7148
-0.004
-0.58%
華盛通- 最 高0.726
- 今 開0.726
- 成交量 3.17万股
- 最 低 0.70
- 昨 收 0.719
- 總市值 532.07万
- 52周最高 7.50
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 0.65
- 委 比 36.40%
- 總股本 744.36万
- 歷史最高 170.00
- 量 比 0.24
- 振 幅 3.62%
- 歷史最低 0.65
- 每 手 1
- 風險率 1.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pasithea Therapeutics Faces Nasdaq Delisting Notice
An announcement from Pasithea Therapeutics Corp ( ($KTTA) ) is now available. O...
06-28 04:41
Kratos Defense & Security Solutions, Inc. Prices Public Offering of Common Stock
<p>Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) has priced an underwritten offering of 12,987,013 shares of its common stock at $38.50 per share, with net proceeds expected to be approximately $483.75 million. The company has granted underwriters a 30-day option to purchase up to an additional 1,948,052 shares. Proceeds will be used to fund investments in national security programs, targeted acquisitions, and general corporate purpose...
06-26 03:14
Pasithea Therapeutics Expands Stock Offering Limit
The latest update is out from Pasithea Therapeutics Corp ( ($KTTA) ). On June 2...
06-21 04:59
Pasithea Adds Drug Expert Dr. James Lee To Guide New Treatment For Crohn's And Other Inflammatory Diseases
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr.
06-11 19:22
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
Pasithea Therapeutics Corp. has appointed Dr. James Lee to its scientific advisory board to guide the development of PAS-004 for treating ETS2-driven inflammatory diseases, including IBD, ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis, and ankylosing spondylitis. Dr. Lee, a leading expert in IBD and a clinician scientist at the Francis Crick Institute, published a 2024 study in Nature identifying ETS2 as a key regulator of ma...
06-11 11:02
Pasithea Announces Its PAS-004 Shows Early Activity And Durable Disease Stability In Heavily Pretreated Solid Tumors, Including BRAF-Mutated Melanoma, With Favorable Safety And Pharmacokinetics In Ongoing Phase 1 Dose Escalation Trial
-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors ---- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who
06-02 20:14
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
PAS-004, a next-generation macrocyclic MEK inhibitor developed by Pasithea Therapeutics, has shown preliminary clinical activity as a monotherapy in heavily pre-treated, refractory solid tumors. Interim Phase 1 study results presented at the 2025 ASCO Annual Meeting highlight stable disease in 10 out of 16 efficacy evaluable patients, with tumor reductions and prolonged survival. Notably, a patient with stage 4 BRAF-mutated melanoma achieved a 14...
06-02 12:02
Pasithea Therapeutics Q1 EPS $(1.61) Up From $(3.70) YoY
Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(1.61) per share. This is a 56.49 percent increase over losses of $(3.70) per share from the same period last year.
05-16 06:32
Pasithea Therapeutics shares are trading higher after the company announced initiation of its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004, in adult participants with neurofibromatosis type 1 with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.
Pasithea Therapeutics shares are trading higher after the company announced ini...
05-14 20:04
Market-Moving News for April 10th
RCAT: -11% | Red Cat Holdings shares are trading lower after the company announced a $30 million registered direct offering of common stock. X: -15% | US Steel shares are trading lower after President
04-10 19:24
